Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

BMC Cancer

Research Article

Anna Sapino¹  Franco Nolè²  Maria Elena Jacomuzzi³  Filippo Montemurro⁴  Rossella Martinello⁴  Stefania Redana⁴  Massimo Aglietta⁴  Giuseppe Viale⁵  Michela Donadio⁶  Alessandra Beano⁶ 

[1] Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, Italy;Department of Medical Oncology, European Institute of Oncology (IEO), Milan, Italy;Division of Gynecology, Mauriziano Hospital, Torino, Italy;Division of Medical Oncology, Institute for Cancer Research and Treatment, Candiolo, Italy;Division of Surgical Pathology and Laboratory Medicine, European Institute of Oncology (IEO), Milan, Italy;Molinette Hospital, Centro Oncologico Subalpino (COES), Turin, Italy;

关键词: Breast Cancer;    Overall Survival;    Docetaxel;    Trastuzumab;    Taxanes;   

DOI  :  10.1186/1471-2407-10-28

 received in 2009-07-01, accepted in 2010-02-01,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundCombinations of trastuzumab with either docetaxel or vinorelbine are considered valuable treatment options for HER2-positive metastatic breast cancer patients. We performed a retrospective comparison of the clinical outcomes associated with either one of these combinations.MethodsFrom a multi-institutional database we retrieved 179 patients treated with either docetaxel or vinorelbine plus trastuzumab as first-line therapy for HER2-positive advanced breast cancer.ResultsDocetaxel-trastuzumab was superior to vinorelbine-trastuzumab in terms of response rate (RR: 77 vs 57%, p = 0.01) and median overall survival (OS: 35 vs 23 months, p = 0.04), but not in median time to progression (TTP: 12 vs 10 months, p = 0.53). At multivariate analysis, type of treatment was not associated with TTP but was an independent predictor of OS, with a significant reduction in the risk of death in favor of docetaxel-trastuzumab (HR 0.474, 95% IC 0,303-0.742, p < 0.01).ConclusionDocetaxel or vinorelbine, when combined with trastuzumab, provide excellent rates of tumor control in patients with previously untreated HER2-positive advanced breast cancer. Docetaxel may offer some advantage in terms of response rate and resulted in a significantly prolonged overall survival, which, because of the retrospective design of our study, deserves further investigation in prospective trials.

【 授权许可】

Unknown   
© Redana et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.